Projects and Manuscripts Edit Test

to define the impact of a novel regulator of strem2 and ad risk/resilience gene on ad pathogenesis and microglia function

identify underlying proteome expression associated with various AT(N) classifications

To determine the relationship between plasma Ab42/Ab40, CSF Ab42/Ab40, and amyloid PET

to quantify the extracellular water in preclinical and early symptomatic AD and investigate its association with cognitive measures

to validate diffusion MRI quantified neuroinflammation with PET PK11195.?

Examining COVID 19 in plasma biomarkers with patients with AD

The goal of this project is to access the performance of SOMAscan ?based protein measurement in comparison to immunoassays based protein measures for CSF biomarkers in AD.

Comparison of ADAD LOAD across the disease spectrum with FC and PCA based approach

Novel way to evaluate longitudinal expansion of WMH in association with AD disease progression

Finalizing results ; Using semiautomated program relate WMH to biomarkers and cognition

To evaluate the temporal ordering of plasma Ab42/Ab40, CSF Ab42, and amyloid PET

To use CSF pTau species to stage preclinical AD

define the impact of a novel ad risk gene in AD pathogenesis

define the impact of a novel ad risk gene in AD pathogenesis and vascular pathology

Identify altered metabolomic reading and patways in LOAD, ADAD

Examine reliability, validity, and feasibility in ARC

to identify targetable pathways that are commonly changed across tau mutations

to use multiple in vitro human cell systems to develop predictive models of moelcular signatures of disease

Develop models of functional connectivity based “brain age” and test differences in symptomatic and preclinical AD

Develop models of “brain age” based on functional and structural MRI. Test relationships with AD biomarkers and cognition

Model tau PET spreading through FC brain networks. Compare group average to subgroup-specific to individual network models.

writing proposal for Charleston conference ;

Patterns of white matter hyperintensities in preclinical AD

Looking at the impact of lifestyle factors such as BMI, and whether the obesity paradox is present across three AD-related cohorts.?

Comparison of the impact of APOE genotype on biomarkers of AD within sporadic and ADAD cohorts

Validating a novel white matter metric of connectivity for understanding breakdown of pathways in preclinical AD.

How does cognitive status moderate the relationship between white matter integrity and attentional control metrics.?

Comparing the Knight ADRC PACC, ADCS PACC, and domain-specific composites derived from the ADRC data.?

Stem cell resource paper

to define the impact of tau mutation on proteostasis

to define the impact of splicing mutation in tau on cellular homeostasis across CNS cell types

To validate the use of CSF and amyloid PET biomarkers for detection of preclinical AD against neuropath dx

To understand how age and genotype impact tau kinetics in organoids

Abstract accepted at ARRS 2022

To profile CSF tau in non-AD tauopathy

How do CSF/plasma levels of NfL and tau relate to one another. Is this relationship mediated through volume?

Under Review

This project aims to examine the influence skull signal may have on quantitative PET analyses using 18F-flortaucpir. Additionally, we determine whether this skull signal can explain some of the sex differences observed in tau PET in the ACS cohort.

To define the impact of TREM2 mutations in stem cell and brains

Leverage Machine Learning and multiple modalities of omics to determine molecular subtypes of AD

We will evaluate the stability of AV45 and PiB amyloid PET tracers for longitudinal analyses using an ICC analysis. We will then create a model for adjusting SUVRs of each tracer when running analyses using longitudinal data with both tracers.

We will use changepoint models to estimate a dynamic temporal ordering of all of the longitudinal biomarker data collected in the ACS program project grant. This will include a global cognitive composite and domain specific cognitive composites from the Clinical Core, CSF biomarkers from Project 2/Biomaker Core of the ACS, (Grant P01AG026276) in combination with the imaging change points in Aim 2b.

Determine the cellular cross-talk dysregulation involving AD genes identified in Genetic Analyses

Evaluate the risk of progression to clinically significant cognitive impairment and relative relationship of race and ethnicity with respect to memory problems in individuals with self-reported and collateral source?reported memory problems

Compare tau PET visual interpretation with tau PET SUVR and CSF p-tau181

Compare TSPO, tau, and A? autoradiography

Compare synaptic, neuronal, and neuroinflammatory biomarkers with A?, tau, and neurodegeneration biomarkers

Compare FreeSurfer software versions and workflows

Compare tau PET positivity models

Abstract accepted AAIC2020 – revise (two manuscript to be submitted) ; Using Oasis data, compare the relationship between baseline amyloid and rate of change and cognition

Abstract accepted AAIC2021

Abstract to be submitted to AAIC2022 and AARF-grant submitted Fall 2021

Investgate the pathways and molecular networks antered in ADAD and LOAD

Determine the brain cell type specific patterns of expression of KDM6A, and X-linked gene that avoids X-inactivation and associated with sex-related differences in AD

To define the impact of non coding RNAs on tauopathy

Determine which pTau isoforms are best correlated with amyloid PET, tau PET, CSF Ab42/Ab40, and structural MRI volumes

Compare prediction of cognitive decline by CSF ptau isoforms and emerging CSF biomarkers

Compare prediction of cognitive decline by CSF and plasma Ab42/Ab40 and NfL

Determine if Klotho heterozygosity (KL-VSHET+) is associated with reduced AD risk and ?-amyloid (A?) pathology in individuals who carry APOE4.